US Pharma MarketingThe post Over half of target patients enrolled in Xeltis’ aXess US pivotal trial appeared first on Medical Device Network.
Over half of target patients enrolled in Xeltis’ aXess US pivotal trial
Xeltis has reached over 50% enrolment in its US pivotal trial of aXess, a vascular access device designed for adults with end-stage renal disease who require haemodialysis. The company plans to enrol a total of 140 patients in the trial of the aXess device. The aXess device is intended to transform into a living blood vessel after implantation, providing long-term access for haemodialysis. Credit: pics five / Shutterstock.com. Xeltis has reached more than 50% enrolment in its US pivotal trial of aXess, a vascular access device designed for adults with end-stage renal disease who require haemodialysis. The ongoing, prospective, multi-centre…
Xeltis has reached over 50% enrolment in its US pivotal trial of aXess, a vascular access device designed for adults with end-stage renal disease who require haemodialysis.
Source: Medical Device Network